Effect of interleukin-1α and tumour necrosis factor-α on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2283-2287

  Li, Qingdi ^a   Bostick Bruton, Frieda ^a   Reed, Eddie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; ERCC 1; Hyperthermia; IL 1 ; Ovarian cancer; TNF

Indexed keywords

CISPLATIN; INTERLEUKIN 1ALPHA; MESSENGER RNA; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; EXCISION REPAIR; GENE INDUCTION; HUMAN; HUMAN CELL; LOW TEMPERATURE; OVARY CARCINOMA; PRIORITY JOURNAL;

CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; KINETICS; OVARIAN NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031811265     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Reed E: The chemotherapy of ovarian cancer. PPO Update 10: 1-12, 1996.
2. Reed E, Dabholkar M, Chabner BA: Platinum Analogues. In: Chabner BA, Longo DL, ed. Cancer Chemotherapy. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 357-378, 1996.
3. Reed E: Platinum Analogs. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer-principles and practice of oncology. 4th ed. Philadelphia: J. B. Lippincott Company 390-400, 1993.
4. Young RC, Perez CA, Hoskins WJ: Cancer of the ovary. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer-principle 4 practice of oncology. Philadelphia: J. B. Lippincott Company 1245-1252, 1993.
5. Lepre CA, Lippard SJ: Interaction of platinum antitumor compounds with DNA. Nucleic Acids Mol Biol 4: 9-38, 1990.
6. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E: Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14: 2177-2180, 1993.
7. Sancar A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
8. Zhen W, Link CJ, O'Connor PM, Reed E: Increased gene-specific repair of cisplatin interstrand crosslinks in cisplatin resistant human ovarian cancer cells. Mol Cell Biol 12: 3689-3698, 1992.
9. Jones JC, Zhen W, Reed E, Parker RJ, Sancar A, Bohr VA: Preferential DNA repair of cisplatinum lesions in active genes in CHO cells. J Biol Chem 266: 7101-7107, 1991.
10. Moggs JG, Yarema KJ, Essigmann JM, Wood RD: Analysis of incision sites produced by human cell extracts and purified proteins during hucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem 271: 7177-7186, 1996.
11. Parker RJ, Eastman A, Bostick-Bruton F, Reed E: Aquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 773-777, 1991.
12. Masuda H, Ozols RF, Lai G-M, Fojo A, Rothenberg M, Hamilton TC: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713-5716, 1988.
13. Pooler CMD, Oosterom ATV, Scalliet PG, Maes RA, Brujin EAD: Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. Biochem Pharmacol 51: 629-634, 1996.
14. Hill BT, Shellard SA, Fichtinger-Schepman AMJ, Schmoll HJ, Harstrick A: Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anti-Cancer Drug 5: 321-328, 1994.
15. Dabholkar M, Bostick-Bruton F, Weber C, Bohr V, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517, 1992.
16. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPA and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
17. Calsou P, Barret J-M, Cros S, Salles B: DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur J Biochem 211: 403-409, 1993.
18. Aboussekhra A: Nucleotide excision repair in vitro and in normal/abnormal human cells. Cell Pharmacol 3: 221-224, 1996.
19. Friedberg EC, Walker GC, Siede W: DNA repair and mutagenesis. Washington DC: ASM Press, 317-326, 1995.
20. Taverna P, Hansson J, Scanlon KJ, Hill BT: Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 15: 2053-2056, 1994.
21. Benchekroun MN, Parker R, Dabholkar M, Reed E, Sinha BK: Effects of interleukin-la on DNA repair in human ovarian carcinoma (NIH:OVCAR-3) cells: Implications in the mechanism of sensitization of cls-diamminedichloroplatinum (II). Mol Pharmacol 47: 1255-1260, 1995.
22. Wang Z, Lee KB, Reed E, Sinha BK: Sensitization by interleukin-1α of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo. Int J Cancer 67: 583-587, 1996.
23. Benchekroun MN, Parker R, Reed E, Sinha BK: Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-la. Biochem. Biophy. Res. Commun. 195: 294-300, 1993.
24. Buell JF, Reed E, Lee KB, Parker RJ, Alexander HR: Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Annals of Surg Oncol 4: 141-148, 1997.
25. Mizutani Y, Bonavida B: Overcoming cls-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 72: 809-818, 1993.
26. van de Vaart PJM, van der Vange N, Zoetmulder FAN, Begg AC: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34: 148-154, 1998.
27. Ohtsubo T, Saito H, Tanaka N, Matsumoto H: Enhancement of cisplatin sensitivity and platinum uptake by 40°C hyperthermia in resistant cells. Cancer Lett 119: 47-52, 1997.
28. Behrens BC, Hamilton TC, Masuda H: Characterization of a cisdiamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418, 1987.
29. Saotome K, Morita H, Umeda M: Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxic in Vitro 3: 317-321, 1989.
30. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
31. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor, 1989.
32. Bonavida B, Safrit J, Morimoto H, Mizutani Y, Uslu R: Cross-resistance of tumor cells to chemotherapy and immunotherapy: approaches to reverse resistance and implications in gene therapy. Oncol Rep 4: 201-205, 1997.
33. Matthews N, Neale ML, Jackson SK, Stark JM: Tumour cell.killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology 62: 153-155, 1987.
34. Uslu R, Bonavida B. Free radicals dependent and independent pathways of CDDP-mediated cytotoxicity and apoptosis in ovarian tumor cell lines. Int J Oncol 6: 1003-1009, 1995.
35. Urano M, Kahn J, Kenton LA: The effect of cisplatin treatment at elevated temperatures on murine fibrosarcoma. F.Sa-II. Int J Hyperthermia 6: 563-570, 1990.
36. Kubota N, Kakehi M, Inada T: Hyperthermic enhancement of cell killing by five platinum complexes in human malignant melanoma cells grown as monolayer cultures and multicellular spheroids. Int J Radiation Oncol 25: 491-497, 1993.
37. Raaphorst GP, Doja S, Davis L, Stewart D, Ng CE: Comparison of cisplatin-hyperthermia sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment. Cancer Chemother Pharmacol 37: 574-580, 1995.
38. Miyahara T, Ueda K, Akaboshi M: Hyperthermic enhancement of cytotoxicity and increased uptake of cis-diamminedichloroplatinum (II) in cultured huma n esophageal cancer cells. Jpn J Cancer Res 84: 336-346, 1993.
39. Supi G, Badaracco G, Cavaliere R, Natali FG, Gerco C: Influence of sequence on hyperthermia and drug combination. Hyperthermic Oncol 1: 429-431, 1994.